 |
0 Diseases |  |
4 Trials |
|
4 Trials |  |
82 News |  |
| «12 |
- chlorthalidone / Generic mfg., candesartan cilexetil / Generic mfg.
Enrollment change, Trial withdrawal: Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control (clinicaltrials.gov) - Jan 19, 2017
P3, N=0, Withdrawn, Sponsor: EMS
N=399 --> 0 | Not yet recruiting --> Withdrawn
- candesartan cilexetil / Generic mfg.
Enrollment change, Trial withdrawal: Efficacy and Safety of Candesartan Associated With Chlorthalidone Versus Losartan Associated With Hydrochlorothiazide (Hyzaar (clinicaltrials.gov) - Jan 19, 2017
P3, N=0, Withdrawn, Sponsor: EMS
N=399 --> 0 | Not yet recruiting --> Withdrawn N=282 --> 0 | Not yet recruiting --> Withdrawn
- ||||| chlorthalidone / Generic mfg., candesartan cilexetil / Generic mfg.
Trial initiation date, Trial primary completion date: Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control (clinicaltrials.gov) - Jul 27, 2016
P3, N=399, Not yet recruiting, Sponsor: EMS
N=282 --> 0 | Not yet recruiting --> Withdrawn Initiation date: Apr 2016 --> Nov 2016 | Trial primary completion date: Oct 2016 --> May 2017
- ||||| candesartan cilexetil / Generic mfg.
Trial initiation date, Trial primary completion date: Efficacy and Safety of Candesartan Associated With Chlorthalidone Versus Losartan Associated With Hydrochlorothiazide (Hyzaar (clinicaltrials.gov) - Jul 27, 2016
P3, N=282, Not yet recruiting, Sponsor: EMS
Initiation date: Apr 2016 --> Nov 2016 | Trial primary completion date: Oct 2016 --> May 2017 Initiation date: Apr 2016 --> Nov 2016 | Trial primary completion date: Oct 2016 --> May 2017
- ||||||| NN1213 / Novo Nordisk
Trial completion, Monotherapy: Antihypertensive Efficacy and Safety of Approved Drugs in Japanese Patients With Essential Hypertension (Banyu Study)(0954A-302) (clinicaltrials.gov) - Feb 27, 2016
P3, N=840, Completed, Sponsor: Merck Sharp & Dohme Corp.
Initiation date: Apr 2016 --> Nov 2016 | Trial primary completion date: Oct 2016 --> May 2017 No longer recruiting --> Completed
- amlodipine/atorvastatin / Generic mfg., losartan/ hydrochlorothiazide / Generic mfg.
Enrollment open: The SCCS Polypill Pilot Trial (clinicaltrials.gov) - Feb 3, 2016
P2, N=300, Recruiting, Sponsor: Vanderbilt University
No longer recruiting --> Completed Not yet recruiting --> Recruiting
- losartan/ hydrochlorothiazide / Generic mfg.
Trial primary completion date, Combination therapy: Comparison of Effects Between Amlodipine and Hydrochlorothiazide in Combination With Losartan on 24-hr Central Blood Pressure in Hypertensive Patients (clinicaltrials.gov) - Sep 24, 2015
P4, N=238, Recruiting, Sponsor: Chong-Jin Kim
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2015 --> Sep 2016
- |||||||||| chlorthalidone / Generic mfg., candesartan cilexetil / Generic mfg.
New P3 trial: Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control (clinicaltrials.gov) - Aug 13, 2015
P3, N=399, Not yet recruiting, Sponsor: EMS
- |||||||||| candesartan cilexetil / Generic mfg.
New P3 trial: Efficacy and Safety of Candesartan Associated With Chlorthalidone Versus Losartan Associated With Hydrochlorothiazide (Hyzaar (clinicaltrials.gov) - Aug 13, 2015
P3, N=282, Not yet recruiting, Sponsor: EMS
- amlodipine/atorvastatin / Generic mfg., losartan/ hydrochlorothiazide / Generic mfg.
Trial initiation date, Trial primary completion date: The SCCS Polypill Pilot Trial (clinicaltrials.gov) - Jun 11, 2015
P2, N=300, Not yet recruiting, Sponsor: Vanderbilt University
Trial primary completion date: Jun 2015 --> Sep 2016 Initiation date: Dec 2014 --> Oct 2015 | Trial primary completion date: Dec 2017 --> Dec 2018
- losartan/ hydrochlorothiazide / Generic mfg.
Enrollment change: Losartan Versus Hydrochlorothiazide in Reversing Remodeling of Small Arteries in Pre-Hypertensive Pre-Diabetic Subjects (clinicaltrials.gov) - May 19, 2015
P2, N=1, Terminated, Sponsor: Sir Mortimer B. Davis - Jewish General Hospital
Initiation date: Dec 2014 --> Oct 2015 | Trial primary completion date: Dec 2017 --> Dec 2018 N=30 --> 1
- losartan/ hydrochlorothiazide / Generic mfg.
Trial completion, Enrollment change, Combination therapy, Monotherapy: Kanagawa Combination Anti-hypertensive Therapy (K-CAT) (clinicaltrials.gov) - Jan 30, 2015
P4, N=196, Completed, Sponsor: Yokohama City University Medical Center
N=30 --> 1 Recruiting --> Completed | N=300 --> 196
- | losartan/ hydrochlorothiazide / Generic mfg.
New P4 trial, Combination therapy: Comparison of Effects Between Amlodipine and Hydrochlorothiazide in Combination With Losartan on 24-hr Central Blood Pressure in Hypertensive Patients (clinicaltrials.gov) - Nov 19, 2014
P4, N=238, Recruiting, Sponsor: Chong-Jin Kim
- ||||| losartan/ hydrochlorothiazide / Generic mfg.
Enrollment change: Evaluate the Safety and Anti-Hypertensive Efficacy of Hyzaar(R) In Patients With Mild To Moderate Essential Hypertension (0954A-323) (clinicaltrials.gov) - Oct 30, 2014
P3, N=62, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed | N=300 --> 196 N=30 --> 62
- | amlodipine/atorvastatin / Generic mfg., losartan/ hydrochlorothiazide / Generic mfg.
New P2 trial: The SCCS Polypill Pilot Trial (clinicaltrials.gov) - Oct 30, 2014
P2, N=300, Not yet recruiting, Sponsor: Vanderbilt University
- |||||||||| New P3 trial: Telmisartan Compared to Losartan + Hydrochlorothiazide in Patients With Mild-to-moderate Essential Hypertension (clinicaltrials.gov) - Jul 8, 2014
P3, N=715, Completed, Sponsor: Boehringer Ingelheim
- ||||| New P4 trial: Telmisartan With or Without Hydrochlorothiazide (HCTZ) Compared With Losartan With or Without HCTZ in Mild to Moderate Hypertensive Patients (clinicaltrials.gov) - Jun 27, 2014
P4, N=363, Completed, Sponsor: Boehringer Ingelheim
- |||| Trial completion: Telmisartan With or Without Hydrochlorothiazide (HCTZ) Compared With Losartan With or Without HCTZ in Mild to Moderate Hypertensive Patients (clinicaltrials.gov) - Jun 27, 2014
P4, N=363, Completed, Sponsor: Boehringer Ingelheim
N=30 --> 62 Not yet recruiting --> Completed
- | Enrollment change: A Randomized, Double-blind, Parallel-group Assessment of the Safety and Efficacy of Telmisartan 40mg Plus Hydrochlorothiazide 12.5mg (Micardis Plus) in Comparison With Losartan 50mg Plus Hydrochlorothiazide 12.5mg in Taiwanese Patients With Mild to Moderate Hypertension (clinicaltrials.gov) - Nov 17, 2013
P3, N=31, Completed, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Completed N=40 --> 31
- ||||| losartan/ hydrochlorothiazide / Generic mfg.
Trial initiation date: Comparison of Losartan Associated With Indapamide Versus Hyzaar (clinicaltrials.gov) - Aug 19, 2013
P3, N=255, Not yet recruiting, Sponsor: EMS
N=40 --> 31 Initiation date: Jun 2013 --> Jan 2014
- ||||| losartan/ hydrochlorothiazide / Generic mfg.
Enrollment change: Comparison of Losartan Associated With Indapamide Versus Hyzaar (clinicaltrials.gov) - Aug 19, 2013
P3, N=255, Not yet recruiting, Sponsor: EMS
Initiation date: Jun 2013 --> Jan 2014 N=195 --> 255
- amlodipine besilate / Generic mfg., losartan/ hydrochlorothiazide / Generic mfg.
Trial completion: Bioequivalence Study of Amlodipine / Losartan/ Hydrochlorothiazide of PHARMALINE, Lebanon Under Fastion Conditions (clinicaltrials.gov) - Jul 23, 2013
P1, N=39, Completed, Sponsor: Pharmaceutical Research Unit, Jordan
N=195 --> 255 Recruiting --> Completed
- losartan/ hydrochlorothiazide / Generic mfg.
Enrollment change, Monotherapy: Pathway 1: Monotherapy Versus Dual Therapy for Initial Treatment for Hypertension (clinicaltrials.gov) - Jun 10, 2013
P4, N=600, Recruiting, Sponsor: University of Cambridge
Recruiting --> Completed N=472 --> 600
- losartan/ hydrochlorothiazide / Generic mfg.
Enrollment open, Monotherapy: Pathway 1: Monotherapy Versus Dual Therapy for Initial Treatment for Hypertension (clinicaltrials.gov) - Jun 10, 2013
P4, N=600, Recruiting, Sponsor: University of Cambridge
N=472 --> 600 Not yet recruiting --> Recruiting
- losartan/ hydrochlorothiazide / Generic mfg.
Enrollment change: PKLH: Pharmacokinetic Interactions of Losartan and Hydrochlorothiazide (clinicaltrials.gov) - May 23, 2013
P=N/A, N=18, Completed, Sponsor: Damanhour University
Not yet recruiting --> Recruiting N=24 --> 18
- amlodipine besilate / Generic mfg., losartan/ hydrochlorothiazide / Generic mfg.
New P1 trial: Bioequivalence Study of Amlodipine / Losartan/ Hydrochlorothiazide of PHARMALINE, Lebanon Under Fastion Conditions (clinicaltrials.gov) - Oct 23, 2012
P1, N=39, Completed, Sponsor: Pharmaceutical Research Unit, Jordan
- ||| atorvastatin / Generic mfg., losartan/ hydrochlorothiazide / Generic mfg.
New P1 trial: Clinical Assessment Of Association Pharmacokinetics Atorvastatin + Losartana + Hydrochlorothiazide (clinicaltrials.gov) - Sep 23, 2012
P1, N=90, Not yet recruiting, Sponsor: L.A.L Clinica Pesquisa e Desenvolvimento Ltda.
- losartan/ hydrochlorothiazide / Generic mfg.
Enrollment change, Monotherapy: A Study of Losartan Compared to Losartan/HCTZ in Pediatric Patients With Hypertension (0954A-327) (clinicaltrials.gov) - Aug 30, 2012
P3, N=40, Terminated, Sponsor: Merck Sharp & Dohme Corp.
N=24 --> 18 N=600 --> 40
- |||||||||| losartan/ hydrochlorothiazide / Generic mfg.
New P3 trial: Comparison of Losartan Associated With Indapamide Versus Hyzaar (clinicaltrials.gov) - Jun 13, 2012
P3, N=255, Not yet recruiting, Sponsor: EMS
- losartan/ hydrochlorothiazide / Generic mfg.
Trial termination, Monotherapy: A Study of Losartan Compared to Losartan/HCTZ in Pediatric Patients With Hypertension (0954A-327) (clinicaltrials.gov) - Feb 8, 2012
P3, N=40, Terminated, Sponsor: Merck Sharp & Dohme Corp.
N=600 --> 40 Withdrawn --> Terminated; Achieving site readiness and enrolling the trial within a reasonable time